Bone Material Comparison in Maxillary Sinus Augmentation
NCT ID: NCT04433117
Last Updated: 2024-03-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2020-06-17
2023-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Scaffolding materials such as xenografts or synthetics substitutes have been proven to be a viable alternative.
Xenografts are obtained from nonhuman species and serve as a scaffold for the formation of new bone (osteoconduction). Histologic evaluation of maxillary sinuses grafted with xenografts revealed newly formed bone to be mostly woven bone with some remodeling to lamellar bone. These histologic findings reaffirm the osteoconductive ability of xenografts when used as the sole grafting material in maxillary sinus augmentation. Xenografts appear to be an effective method for maxillary sinus grafting and demonstrate limited resorption over time. Sinuses augmented with synthetic bone substitute (SBS) also appear to successfully integrate based on recent histomorphometric studies. Vascularization and trabecular bone formation in sinuses grafted with SBS has been previously demonstrated. One type of SBS includes porous granules of bioactive and resorbable silica-calcium phosphate nanocomposite (ShefaBone). ShefaBone grafts offer a novel alternative that can potentially unite the 3 salient bone-forming properties (osteoinduction, osteoconduction, and osteogenesis). ShefaBone has unique properties including: 1) bioactivity 2) bioresorbablility, and 3) allowing for the uptake of calcium ions from the physiological solution and releasing phosphate and silicate ions which aid in bone formation. A material with such properties will substitute bone in a more controlled and effective combination that can be obtained in many clinical situations, without the disadvantages found with autograft. ShefaBone has demonstrated successful regenerative properties for bony defects. To our knowledge, there is no reported clinical studies on the use of SCPC material to graft a pneumatized maxillary sinus. This aim of this current study is to compare SCPC to commonly used xenograft material in an augmented maxillary sinus.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiographic and Histomorphometric Assessment for Maxillary Sinus Floor Elevation and Augmentation Using A Mixture of 1:1 Autogenous Bone With Deproteinized Bovine Bone Particulate Versus Deproteinized Bovine Bone Particulate
NCT07177495
Assessment of the Quality and Quantity of Bone Regeneration
NCT03417375
Evaluation of Sinus Augmentation Bone Healing Using Autograft and Xenograft Compared to Xenograft Alone
NCT06247098
Osteotome-mediated Sinus Floor Elevation With or Without Grafting Material
NCT04618900
The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation
NCT06533397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. With the use of pre-operative and post-operative limited view CBCT (cone-beam computed tomography) radiography, the maxillary sinus bone density will be assessed and compared between the individuals receiving Shefabone and the individuals receiving xenograft material.
3. Histomorphometric analysis will be used to assess, compare and contrast the quality and the quantity of the new vital bone cells generated when using these different graft materials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
Bio-Oss
Xenograft Bone substitute. Bone from animals.
Test Group
The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
Shefabone
Silica-calcium phosphate composite.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shefabone
Silica-calcium phosphate composite.
Bio-Oss
Xenograft Bone substitute. Bone from animals.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least one maxillary edentulous posterior site requiring maxillary sinus grafting and replacement with a dental implant.
Exclusion Criteria
* are pregnant
* have active periodontal disease
* have uncontrolled diabetes
* have any autoimmune disease
* have kidney disease
* have liver disease
* are receiving radiation or chemotherapy
* have any type of radiographic periapical pathology such as a periapical abscess.
20 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mohanad Al-Sabbagh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohanad Al-Sabbagh
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohanad Al-Sabbagh, DDS
Role: PRINCIPAL_INVESTIGATOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
58349
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.